RYTHM, Inc (RYM) Fair Value & Analysis
Consumer Defensive · US · Market cap $55.8M
Fair value as of: Jun 24, 2026
Analysis
RYTHM, Inc (RYM) currently trades at $25.36, while our model-based Fair Value estimate is $33.32 — implying the stock looks roughly 31.4% undervalued today. We read business quality at 95/100 (high quality), in the Consumer Defensive sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.
About the company
RYTHM, Inc. provides solutions for the cannabis and hemp industry in the United States. The company offers consumers hemp-derived tetrahydrocannabinol beverages, as well as other hemp-derived products through retailers, online, and direct-to-retail partnerships. It also provides cocktails in four flavors, such as classic Lime Jalapeño Margarita, Mango Margarita, Paloma, and Ranch Water; and an alternative to alcoholic beverages, such as Total Wine, ABC Fine Wine & Spirits, and Binny's. In addition, the company licenses its brands to be manufactured and distributed. It sells its products under the RYTHM, incredibles, Dogwalkers, Beboe, &Shine, Doctor Solomon's, Good Green, and Señorita brands. The company was formerly known as Agrify Corporation and changed its name to RYTHM, Inc. in August 2025. RYTHM, Inc. was incorporated in 2016 and is headquartered in Rolling Meadows, Illinois.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is RYTHM, Inc (RYM) undervalued?
What is the fair value of RYM?
What is the quality score of RYM?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.